Clincosm LogoSign in Get a demo

Assessment of Rosacea Patients' Clinical Trial Experiences

Sponsor
Power Life Sciences Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05747391
Collaborator
(none)
500
Enrollment
24
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This study will admit a wide range of data on the clinical trial experience of Rosacea patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Rosacea patients.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    An Evaluation of Medical Study Experiences of Patients With Rosacea
    Anticipated Study Start Date :
    Mar 17, 2023
    Anticipated Primary Completion Date :
    Mar 17, 2024
    Anticipated Study Completion Date :
    Mar 17, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Rate of patients who decide to join in an Rosacea clinical study [3 months]

    2. Number of Rosacea patients who remain in clinical trial until completion [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patient is at least 18 years of age

    • Diagnosis of Rosacea

    • Ability to understand the study procedures, benefits and risks, and sign a written informed consent document.

    Exclusion Criteria:

    • Inability to perform regular electronic reporting

    • Women who are pregnant, intend to become pregnant, or are lactating

    • Inability to perform regular electronic reporting

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Power Life Sciences Inc.

    Investigators

    • Study Director: Michael B Gill, Power Life Sciences Inc.

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    Power Life Sciences Inc.
    ClinicalTrials.gov Identifier:
    NCT05747391
    Other Study ID Numbers:
    • 83850357
    First Posted:
    Feb 28, 2023
    Last Update Posted:
    Feb 28, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Power Life Sciences Inc.
    Rosacea
    Additional relevant MeSH terms:
    Rosacea

    Study Results

    No Results Posted as of Feb 28, 2023